Damaging the conical morphology of HIV-1 capsid by targeting the FG-binding pocket and disfavoring pentameric subunits needed for core closure

This study reveals that the FGBP-binding inhibitor ZW-1261 disrupts HIV-1 capsid integrity by converting essential pentameric subunits into hexamer-like conformations, thereby preventing the formation of closed conical cores.

The Gist

The Big Picture: Breaking the Virus's "Suitcase"

Imagine the HIV virus is a tiny, sophisticated spy. To do its job, it needs to sneak into a human cell and deliver a secret package (its genetic code) to the cell's control center. To protect this package during the journey, the virus builds a hard, geometric shell around it called the capsid.

Think of this capsid as a 3D puzzle suitcase.

• The Hexagons (CAHEX): Most of the suitcase is made of flat, six-sided tiles (hexagons). These make up the long, straight sides of the cone.
• The Pentagons (CAPENT): To make the suitcase curve and close up at the top and bottom, you need exactly 12 five-sided tiles (pentagons). Without these, the suitcase would just be an open tube that never closes.

The virus needs this suitcase to be perfectly shaped to survive the trip through the cell and unlock the door to the nucleus. If the suitcase is broken, the virus dies.

The New Weapon: ZW-1261

Scientists have been trying to find a way to break this suitcase. They already know about a powerful drug called Lenacapavir (LEN) that jams a specific lock on the suitcase tiles. This paper studies a new, even more potent "lock-jammer" called ZW-1261.

The researchers wanted to understand exactly how ZW-1261 destroys the virus's suitcase.

The Discovery: Two Opposing Forces

The virus uses a special helper molecule called IP6 (think of it as "glue" or "mortar") to help build the pentagons (the curved corners) and close the suitcase.

The researchers found that ZW-1261 and IP6 are like two people pulling a rope in opposite directions:

1. IP6 (The Builder): Wants to build the curved corners (pentagons) and close the suitcase.
2. ZW-1261 (The Destroyer): Wants to force the tiles to stay flat and straight, turning the suitcase into an open, endless tube.

The Experiment: What Happens When They Mix?

The scientists ran several experiments to see what happens when they mix these ingredients:

• Scenario A: The Drug Alone
  When they added ZW-1261 to the virus proteins without any glue, the proteins immediately snapped together into long, open tubes. It was like trying to build a dome but the bricks refused to curve; they just made a straight pipe.

• Scenario B: The Drug vs. The Glue (Simultaneous)
  When they added the drug and the glue at the same time (mimicking how the virus is made inside a cell), the result was a mess. They got weird, broken shapes—elongated cones that were cracked and couldn't close properly. The drug was fighting the glue, and the suitcase fell apart.

• Scenario C: The Drug on a Finished Suitcase
  When they built a perfect suitcase first using glue, and then added the drug, the drug attacked the finished product. It broke the lattice, and the "pentagon" corners disappeared. The virus couldn't hold its shape.

The Secret Mechanism: The "Molecular Switch"

The most fascinating part of the paper is how the drug does this.

The virus has a tiny switch on its tiles (a loop of amino acids called the TVGG switch).

• In a Hexagon (Flat tile): The switch is short.
• In a Pentagon (Curved tile): The switch is long and stretched out. This stretching is what allows the tile to bend and form a corner.

The Magic of ZW-1261:
The drug binds to the tile and physically forces that "long switch" to snap back into the "short" position.

• Even if the tile is part of a pentagon (a corner), the drug forces it to act like a hexagon (a flat side).
• It's like forcing a curved brick to become flat. If you try to build a dome with flat bricks, the dome collapses.

Why This Matters

This research explains why drugs like Lenacapavir and ZW-1261 are so effective. They don't just stop the virus from building; they actively sabotage the geometry of the virus.

By forcing the virus to forget how to make its curved corners (pentagons), the drug ensures the virus's "suitcase" can never close. Without a closed suitcase, the virus's genetic code is exposed and destroyed by the cell's defenses.

In short: The virus tries to build a dome. The drug forces the bricks to stay flat, turning the dome into a broken pipe, and the virus fails to infect the cell.

Technical Summary

1. Problem Statement

The HIV-1 capsid (CA) is a critical viral component essential for replication, immune evasion, and nuclear entry. It forms a conical lattice composed of approximately 250 hexamers (CAHEX) and exactly 12 pentamers (CAPENT). The balance between these two oligomeric states is crucial: CAHEX forms the elongated body of the cone, while CAPENT introduces the curvature necessary to close the core.

• The Challenge: While the capsid is a validated drug target (e.g., by Lenacapavir), the precise molecular mechanism by which FGBP (Phenylalanine-Glycine binding pocket) inhibitors disrupt the specific geometry required for capsid closure remains incompletely understood. Specifically, how these inhibitors affect the structural switch between CAHEX and CAPENT, and whether they can force a conformational change in pre-formed pentamers, requires further elucidation.
• The Gap: Previous studies established that inhibitors bind the FGBP, but the antagonistic relationship between FGBP-targeting drugs (which favor hexamers) and polyanionic cofactors like Inositol Hexaphosphate (IP6) (which favor pentamers and core closure) needed structural resolution.

2. Methodology

The authors employed a multidisciplinary approach combining structural biology, biophysics, and virology:

• In Vitro Assembly Assays: Used absorbance at 350 nm ($A_{350}$) to monitor the kinetics of CA lattice formation under varying conditions (NaCl induction, pH 8.0, presence of compounds).
• Thermal Shift Assays (TSA): Measured the melting temperature ($\Delta T_m$) of CA hexamers to quantify the stabilizing effects of FGBP inhibitors (ZW-1261, Lenacapavir, PF74) and central pore binders (IP6, HCB) alone and in combination.
• Negative Stain Transmission Electron Microscopy (TEM): Visualized the morphology of assembled particles (tubes, cones, irregular aggregates) under different treatment conditions (ZW-1261 alone, IP6 alone, co-assembly, and sequential treatment).
• Cryo-Electron Microscopy (Cryo-EM):
  • CLPs: Solved structures of Capsid-Like Particles (CLPs) assembled with IP6 and treated with ZW-1261.
  • T=1 Icosahedrons: Utilized a mutant CA construct (G60A/G61P) that forces the formation of CAPENT-only T=1 icosahedrons. These were treated with ZW-1261 to resolve the drug-pentamer interface at high resolution (2.32 Å).
• Native Mass Spectrometry (nMS): Determined the stoichiometry of ligand binding (ZW-1261 and IP6) to CA hexamers to confirm simultaneous occupancy.

3. Key Contributions

• Identification of ZW-1261 as a Potent Assembly Initiator: Demonstrated that ZW-1261 (a PF74 analog) can spontaneously induce CA assembly into tubular structures at pH 8.0 without salt, a condition that typically prevents assembly. This is attributed to its unique R3 indole modification bridging adjacent monomers via a coordinated water molecule.
• Structural Mechanism of Pentamer Disruption: Provided the first high-resolution structural evidence that FGBP-binding inhibitors can bind to CAPENT, but only by forcing a conformational change that mimics the CAHEX state.
• Antagonism of IP6 and FGBP Inhibitors: Defined the mechanistic conflict where IP6 promotes the curvature (pentamers) needed for closure, while FGBP inhibitors promote the straightness (hexamers) needed for elongation, leading to lattice damage when both are present in mature cores.

4. Key Results

• Assembly Kinetics and Morphology:
  • ZW-1261 Alone: Rapidly induces the formation of open-ended tubes (CAHEX-only) at pH 8.0, indicating a strong bias toward hexameric assembly.
  • Co-assembly (IP6 + ZW-1261): Results in irregular, elongated, and closed tubes, suggesting a mixture of hexamers and pentamers but failing to form perfect conical cores.
  • Sequential Treatment (Pre-formed CLPs + ZW-1261): When added to pre-assembled, IP6-stabilized CLPs, ZW-1261 causes lattice damage, resulting in broken, irregular particles. Cryo-EM analysis of these damaged particles revealed the absence of CAPENT classes, suggesting the drug disassembles or prevents the formation of pentamers in an existing lattice.
• Thermodynamic Stability:
  • ZW-1261 and IP6 individually stabilize CAHEX.
  • Additive Stabilization: When combined, they provide significantly higher thermal stability ($\Delta T_m \approx 20.7^\circ$C for IP6+ZW-1261) compared to either alone, confirming they can occupy their respective pockets (FGBP and central pore) simultaneously on a hexamer.
• Structural Insights into CAPENT:
  • The "TVGG" Switch: In native CAPENT, the loop residues 58-TVGG-61 form an elongated $\alpha$-helix, sterically blocking the FGBP.
  • ZW-1261 Binding to Pentamers: Using the G60A/G61P mutant (which forces a pentameric state), the authors solved a structure showing ZW-1261 binding to the FGBP. Crucially, the binding forces the Thr58 residue to adopt a CAHEX-like conformation, effectively "breaking" the pentameric switch.
  • Consequence: The drug converts the local structure of the pentamer to resemble a hexamer. Since the global lattice geometry requires pentamers to close the cone, converting them to a hexamer-like state prevents core closure or destabilizes the existing closed core.
• Comparison to Lenacapavir: The mechanism observed for ZW-1261 mirrors that of Lenacapavir, explaining why Lenacapavir also leads to lattice fractures and loss of curvature in mature virions.

5. Significance

• Mechanistic Clarity: This study elucidates a "molecular tug-of-war" mechanism. The HIV-1 capsid requires a precise equilibrium between hexamers (for elongation) and pentamers (for closure). FGBP inhibitors tip this balance heavily toward hexamers.
• Therapeutic Implications: The findings explain the high potency of long-acting capsid inhibitors like Lenacapavir. By binding the FGBP, these drugs do not just stabilize the lattice; they actively prevent the formation of pentamers or convert existing pentamers into hexamer-like conformations, thereby preventing the virus from forming a closed, infectious core.
• Drug Design: The study highlights the importance of the R3 indole ring in PF74 analogs (specifically the hydroxyl group in ZW-1261) for bridging monomers and driving assembly. This provides a blueprint for designing next-generation inhibitors that maximize this "assembly-inducing" and "closure-disrupting" effect.
• Resistance Understanding: The structural data helps explain resistance mutations (e.g., M66I) which likely alter the equilibrium between the open (hexamer) and closed (pentamer) states of the FGBP, affecting drug binding efficacy.

In summary, the paper demonstrates that FGBP-targeting antivirals act as "morphological disruptors" that favor the hexameric state, thereby preventing the geometric closure of the HIV-1 capsid and leading to non-infectious, damaged viral particles.